IFNB1 and dermatomyositis: In a recent publication, extensive profiling of dermatomyositis skin was performed and lenabasum was found to downregulate CD4-positive T cells, IFN-β, IFN-γ, IL-31 and pathophysiological CB2 receptor expression, while a similar effect was not observed in healthy skin [8].